Medicines regulator not planning to suspend J&J shot after US flags risk of rare neurological condition
Guillain-Barre syndrome is a disorder in which the body’s immune system attacks the nervous system, causing muscle weakness and potential paralysis
14 July 2021 - 20:23
SA’s medicines regulator says it does not anticipate suspending use of the Johnson & Johnson (J&J) coronavirus vaccine after US authorities warned earlier this week of a possible association with a rare neurological condition called Guillain-Barre syndrome.
The J&J shot is one of two vaccines being administered in the national coronavirus inoculation drive and is central to the government’s plans to reach 70% of the adult population by March 2022...
BL Premium
This article is reserved for our subscribers.
A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.
Already subscribed? Simply sign in below.
Questions or problems? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now